8 hrs ago
Mylan Announces Pricing of $1.15B in Senior Notes; Refinancing...
Mylan today announced the pricing of a private placement of $500 million aggregate principal amount of 1.80% Senior Notes due 2016 at an issue price of 99.925% and $650 million aggregate principal amount of 2.60% Senior Notes due 2018 at an issue price of 99.791%.
16 hrs ago
Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost...
Pro football player and 2012 most valuable player Adrian Peterson and professional family expert Jo Frost have potentially life-threatening allergies and are partnering with Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. , to raise awareness of this significant health problem.
Wed Jun 12, 2013
Mylan Inc. to Speak at the Goldman, Sachs & Co. 34th Annual Global Healthcare Conference
The conference will be webcast live and can be accessed on Mylan's Investor Relations Web site at http://investor.mylan.com/ .
Sat Jun 08, 2013
NASDAQ Active Stock Watch List: MannKind Corp. (NASDAQ:MNKD), Mylan,...
Growing Stock Report expands its NASDAQ Active Stock Watch List adding MannKind Corp. , Mylan, Inc. , and Vical Incorporated .
Wed Jun 05, 2013
Mylan Price Target Increased to $38.00 by Analysts at JP Morgan Cazenove
The firm currently has an "overweight" rating on the stock. JP Morgan Cazenove's target price would indicate a potential upside of 27.13% from the company's current price.
JP Morgan Raises PT on Mylan as the Company Looks for Acquisitions
In a report published on Wednesday analysts from JP Morgan raised its price target on Mylan from $34 to $38 and maintained an Overweight rating on the company.
Tue May 21, 2013
Court rules in favor of Mylan in patent case
An appellate court has upheld five patents for Mylan Specialty L.P., reversing a district court's summary judgment affecting the company's Perforomist medication, which is used to treat breathing problems.
Mylan begins drug shipments
Mylan Pharmaceuticals has started shipping fenofibrate tablets in two strengths after receiving final approval from the Food and Drug Administration, the Canonsburg company announced.